Wall Street analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to post earnings per share (EPS) of ($2.09) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Blueprint Medicines’ earnings. The lowest EPS estimate is ($2.16) and the highest is ($2.03). Blueprint Medicines reported earnings of ($2.04) per share in the same quarter last year, which would indicate a negative year over year growth rate of 2.5%. The firm is expected to report its next earnings report on Thursday, August 6th.
On average, analysts expect that Blueprint Medicines will report full-year earnings of ($8.40) per share for the current year, with EPS estimates ranging from ($8.77) to ($8.25). For the next financial year, analysts anticipate that the business will report earnings of ($6.80) per share, with EPS estimates ranging from ($8.29) to ($4.15). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.08) by ($0.03). The business had revenue of $6.20 million during the quarter, compared to analysts’ expectations of $5.57 million. Blueprint Medicines had a negative net margin of 515.98% and a negative return on equity of 65.81%. Blueprint Medicines’s revenue for the quarter was up 749.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.98) EPS.
In other Blueprint Medicines news, Director Nicholas Lydon sold 13,017 shares of Blueprint Medicines stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $80.29, for a total value of $1,045,134.93. Following the transaction, the director now owns 89,039 shares in the company, valued at approximately $7,148,941.31. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $64.67, for a total value of $1,293,400.00. Following the sale, the chief executive officer now owns 161,434 shares of the company’s stock, valued at $10,439,936.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,217 shares of company stock worth $2,578,985. 3.81% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the business. Bourgeon Capital Management LLC acquired a new position in shares of Blueprint Medicines in the 1st quarter valued at about $29,000. Advisor Group Holdings Inc. purchased a new stake in Blueprint Medicines during the first quarter worth approximately $32,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $46,000. Quantbot Technologies LP raised its stake in shares of Blueprint Medicines by 80.0% in the 4th quarter. Quantbot Technologies LP now owns 900 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 400 shares during the period. Finally, US Bancorp DE lifted its holdings in shares of Blueprint Medicines by 49.7% during the 4th quarter. US Bancorp DE now owns 1,430 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 475 shares in the last quarter. Institutional investors own 97.95% of the company’s stock.
Shares of Blueprint Medicines stock traded up $0.13 during trading hours on Friday, reaching $79.15. 265,494 shares of the company’s stock were exchanged, compared to its average volume of 767,645. The business has a fifty day moving average of $71.22 and a two-hundred day moving average of $67.59. The company has a quick ratio of 7.14, a current ratio of 7.17 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $4.29 billion, a P/E ratio of -10.65 and a beta of 1.09. Blueprint Medicines has a 1 year low of $43.29 and a 1 year high of $102.98.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.